EA202190722A1 - Клинические композиции - Google Patents

Клинические композиции

Info

Publication number
EA202190722A1
EA202190722A1 EA202190722A EA202190722A EA202190722A1 EA 202190722 A1 EA202190722 A1 EA 202190722A1 EA 202190722 A EA202190722 A EA 202190722A EA 202190722 A EA202190722 A EA 202190722A EA 202190722 A1 EA202190722 A1 EA 202190722A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tissue
medical
compositions
cell
cells
Prior art date
Application number
EA202190722A
Other languages
English (en)
Inventor
Роджер Гэй
Ромма Е. Саутвик
Джадсон Ратлифф
Original Assignee
Астеллас Инститьют Фор Ридженерэйтив Медсин
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Инститьют Фор Ридженерэйтив Медсин filed Critical Астеллас Инститьют Фор Ридженерэйтив Медсин
Publication of EA202190722A1 publication Critical patent/EA202190722A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • A01N1/021Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04Preserving or maintaining viable microorganisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0621Eye cells, e.g. cornea, iris pigmented cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/60Buffer, e.g. pH regulation, osmotic pressure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Dentistry (AREA)

Abstract

В некоторых аспектах настоящее изобретение относится к медицинским средам, которые поддерживают жизнеспособность, эффективность повторного культивирования и репопуляционную способность клеток и тканей во время хранения в течение 48 ч или дольше. Медицинские среды, представленные в изобретении, также применяются для клинического орошения. Также рассмотрены клеточные или тканевые композиции, содержащие клеточную популяцию или ткань и медицинскую среду по изобретению, и способы получения таких композиций. Также раскрыты способы использования медицинских сред и клеточных и тканевых композиций по изобретению, например, для введения эффективного количества клеток или ткани субъекту, нуждающемуся в таком введении.
EA202190722A 2015-08-18 2016-08-18 Клинические композиции EA202190722A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562206821P 2015-08-18 2015-08-18

Publications (1)

Publication Number Publication Date
EA202190722A1 true EA202190722A1 (ru) 2021-10-29

Family

ID=56843032

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202190722A EA202190722A1 (ru) 2015-08-18 2016-08-18 Клинические композиции
EA201890516A EA037915B1 (ru) 2015-08-18 2016-08-18 Клинические композиции

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201890516A EA037915B1 (ru) 2015-08-18 2016-08-18 Клинические композиции

Country Status (16)

Country Link
US (2) US11013808B2 (ru)
EP (1) EP3334415A1 (ru)
JP (3) JP7043392B2 (ru)
KR (3) KR102651291B1 (ru)
CN (1) CN108697641A (ru)
AU (2) AU2016308818B2 (ru)
BR (1) BR112018003031B1 (ru)
CA (1) CA2995977A1 (ru)
EA (2) EA202190722A1 (ru)
HK (1) HK1256839A1 (ru)
IL (3) IL299326A (ru)
MX (2) MX2018002038A (ru)
PH (1) PH12018500371A1 (ru)
SG (1) SG10201913250SA (ru)
TW (3) TW202417023A (ru)
WO (1) WO2017031312A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
IL305070A (en) 2014-12-30 2023-10-01 Cell Cure Neurosciences Ltd RPE cell populations and methods for their production
MX2017012259A (es) 2015-03-23 2018-05-17 Astellas Inst For Regenerative Medicine Ensayos mejorados para la potencia de células epiteliales pigmentarias de retina humana (rpe) y progenitores de fotorreceptores.
IL299326A (en) 2015-08-18 2023-02-01 Astellas Inst For Regenerative Medicine Clinical formulations
CA3028613A1 (en) * 2016-06-30 2018-01-04 Sumitomo Dainippon Pharma Co., Ltd. Transplantation medium
SG11202005795TA (en) * 2017-12-29 2020-07-29 Cell Cure Neurosciences Ltd Retinal pigment epithelium cell compositions
BR112022003659A2 (pt) 2019-08-28 2022-05-24 Astellas Inst For Regenerative Medicine Composições e métodos de tratamento de doenças vasculares
KR20220054359A (ko) 2019-08-28 2022-05-02 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 질병을 치료하는 방법
JP2023500830A (ja) 2019-10-30 2023-01-11 アステラス インスティテュート フォー リジェネラティブ メディシン 網膜色素上皮細胞を生成するための方法
JP7018527B1 (ja) 2020-12-16 2022-02-10 アニコム先進医療研究所株式会社 細胞の保存方法および細胞懸濁液
EP4369929A1 (en) * 2021-07-15 2024-05-22 SiO2 Medical Products, Inc. Preservative composition for nucleic acids and biological samples and methods of use
WO2023176906A1 (ja) * 2022-03-16 2023-09-21 住友ファーマ株式会社 移植用媒体
WO2024019962A1 (en) 2022-07-18 2024-01-25 Astellas Institute For Regenerative Medicine Methods of treating brain injury
WO2024044134A1 (en) 2022-08-23 2024-02-29 Astellas Institute For Regenerative Medicine Photoreceptor rescue cell (prc) compositions and methods for treatment of ocular disorders
WO2024172043A1 (ja) * 2023-02-14 2024-08-22 住友ファーマ株式会社 網膜色素上皮裂孔の治療薬

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654266A (en) 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
DE69227179D1 (de) * 1992-03-27 1998-11-05 Chen Chung Ho Mittel für Gewebe zur Erhaltung der Lebensfähigkeit und biologische Funktionen in der Chirurgie und Lagerung
KR100267604B1 (ko) 1993-06-04 2000-11-01 이 세갈 폴 혈장 유사 용액
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
ATE270096T1 (de) 1997-08-22 2004-07-15 Shimizu Pharma Glukose enthaltende zubereitung
GB2336109A (en) 1998-04-07 1999-10-13 Univ Bristol Ophthalmic Irrigating Solution
DE60024875T2 (de) * 2000-01-11 2006-08-24 Ophtecs Corporation Perfusionslösung zusammensetzungen für ophthalmische verfahren
US7084157B2 (en) * 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
CA2937099A1 (en) 2004-01-23 2005-08-04 Astellas Institute For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
US20190282622A1 (en) 2004-01-23 2019-09-19 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
WO2008020815A1 (en) * 2006-08-15 2008-02-21 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
EP2377923A1 (en) 2006-04-14 2011-10-19 Advanced Cell Technology, Inc. Hemangio-colony forming cells
EP3636748A1 (en) 2007-10-12 2020-04-15 Astellas Institute for Regenerative Medicine Improved methods of producing rpe cells and compositions of rpe cells
KR20110016913A (ko) 2008-05-06 2011-02-18 어드밴스드 셀 테크놀로지, 인코포레이티드 혈관 콜로니 형성 세포 및 비-생착성 혈관 세포
CN102083960B (zh) 2008-05-06 2014-12-03 先进细胞技术公司 用于制备衍生自多能干细胞的去核类红细胞的方法
KR20120102709A (ko) 2009-11-17 2012-09-18 어드밴스드 셀 테크놀로지, 인코포레이티드 인간 rpe 세포의 생산 방법 및 인간 rpe 세포의 제약 제제
IN2012DN05053A (ru) 2009-12-04 2015-10-09 Stem Cell & Regenerative Medicine Internatioinal Inc
AU2010325811A1 (en) 2009-12-04 2012-06-21 Stem Cell & Regenerative Medicine International, Inc. Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions
AU2011280878B2 (en) 2010-07-23 2016-06-16 Astellas Institute For Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
KR102054904B1 (ko) 2011-11-14 2019-12-11 아스텔라스 인스티튜트 포 리제너러티브 메디슨 인간 rpe 세포의 약제학적 제제 및 그의 용도
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CA2857545A1 (en) 2011-11-30 2013-06-06 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
ES2716200T3 (es) 2011-12-06 2019-06-11 Astellas Inst For Regenerative Medicine Método de diferenciación dirigida que produce células endoteliales corneales
CN103783031B (zh) * 2012-10-29 2015-11-18 四川新生命干细胞科技股份有限公司 一种细胞保存液
AU2013201546B2 (en) 2012-12-18 2014-10-23 Gambro Lundia Ab Dialysis composition
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
US20160175362A1 (en) 2014-03-14 2016-06-23 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175361A1 (en) 2014-03-14 2016-06-23 Advanced Cell Technology, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
CA3177943A1 (en) 2013-03-15 2014-09-18 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
AU2015311702A1 (en) 2014-09-05 2017-04-06 Astellas Institute For Regenerative Medicine Retinal ganglion cells and progenitors thereof
MX2017012259A (es) 2015-03-23 2018-05-17 Astellas Inst For Regenerative Medicine Ensayos mejorados para la potencia de células epiteliales pigmentarias de retina humana (rpe) y progenitores de fotorreceptores.
IL299326A (en) * 2015-08-18 2023-02-01 Astellas Inst For Regenerative Medicine Clinical formulations
BR112022003659A2 (pt) 2019-08-28 2022-05-24 Astellas Inst For Regenerative Medicine Composições e métodos de tratamento de doenças vasculares
KR20220054359A (ko) 2019-08-28 2022-05-02 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 질병을 치료하는 방법
JP2023500830A (ja) 2019-10-30 2023-01-11 アステラス インスティテュート フォー リジェネラティブ メディシン 網膜色素上皮細胞を生成するための方法

Also Published As

Publication number Publication date
IL291163B1 (en) 2023-01-01
TWI772270B (zh) 2022-08-01
EP3334415A1 (en) 2018-06-20
IL291163B2 (en) 2023-05-01
BR112018003031B1 (pt) 2023-12-26
IL299326A (en) 2023-02-01
IL257551A (en) 2018-04-30
JP7043392B2 (ja) 2022-03-29
JP7449915B2 (ja) 2024-03-14
TWI833293B (zh) 2024-02-21
AU2022206757A1 (en) 2022-08-18
MX2022010363A (es) 2022-09-21
AU2022206757B2 (en) 2024-09-05
BR112018003031A2 (pt) 2018-09-18
US11957754B2 (en) 2024-04-16
CN108697641A (zh) 2018-10-23
TW201717912A (zh) 2017-06-01
TW202245816A (zh) 2022-12-01
US11013808B2 (en) 2021-05-25
EA201890516A1 (ru) 2018-09-28
CA2995977A1 (en) 2017-02-23
JP2018523682A (ja) 2018-08-23
MX2018002038A (es) 2018-07-06
IL291163A (en) 2022-05-01
KR102411018B1 (ko) 2022-06-20
HK1256839A1 (zh) 2019-10-04
KR20230058544A (ko) 2023-05-03
JP2022040140A (ja) 2022-03-10
US20190030168A1 (en) 2019-01-31
EA037915B1 (ru) 2021-06-07
NZ740608A (en) 2023-09-29
WO2017031312A1 (en) 2017-02-23
AU2016308818B2 (en) 2022-04-21
AU2016308818A1 (en) 2018-04-05
US20210275673A1 (en) 2021-09-09
TW202417023A (zh) 2024-05-01
SG10201913250SA (en) 2020-03-30
PH12018500371A1 (en) 2018-08-29
KR20180048722A (ko) 2018-05-10
IL257551B (en) 2022-04-01
US20190358330A9 (en) 2019-11-28
KR102651291B1 (ko) 2024-03-26
KR20220090583A (ko) 2022-06-29
JP2024074803A (ja) 2024-05-31

Similar Documents

Publication Publication Date Title
EA202190722A1 (ru) Клинические композиции
CY1123343T1 (el) Παραγωγη μιας τραπεζας μεσεγχυματικων στρωματικων κυτταρων απο τα ομαδοποιημενα μονοπυρηνα κυτταρα πολλαπλων δοτων μυελου των οστων
MX2020003351A (es) Metodos, composiciones y elementos implantables que comprenden celulas activas.
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
UY38160A (es) Partículas implantables y métodos relacionados
WO2017163132A3 (en) Use of umbilical cord blood derived exosomes for tissue repair
MX2014014044A (es) Composiciones herbicidas que contienen amidas de acido n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxilico.
BR112014010814A2 (pt) composições de herbicida/fitoprotetor contendo amidas do ácido n-(tetrazol-5-il) aril carboxílico e amidas do ácido n-(triazol-5-il) aril carboxílico
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
EA201201661A1 (ru) Новые аминопиразолохиназолины
EP2603227A4 (en) IMPROVED HEMATOPOETIC TRIBE AND PRECURSOR CELL THERAPY
ECSP12012353A (es) Compuestos, composiciones de tioacetato y métodos de uso
EA201300323A1 (ru) Материалы и способы улучшения функции желудочно-кишечного тракта
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
TR201902218T4 (tr) Fluopiram içeren aktif madde kombinasyonları.
MD3250182T2 (ro) Compoziții dispersabile
CR20150310A (es) Solución para preservar conductos vasculares
BR112015022408A2 (pt) barras de limpeza que compreendem copolímeros anfifílicos super-hidrofílicos, e métodos para uso das mesmas
BR112013028257A2 (pt) "composição de fármaco biológico, métodos de manipulação de uma composição de fármaco biológica com células vivas e de fornecer composições de células vivas em um ponto de instalação de tratamento, bem como uso de células vivas formuladas em tampão não nutritivo"
EA201290759A1 (ru) Антитела
MX2019011545A (es) Composiciones celulares y de andamio inyectables.
JP2016516985A5 (ru)
IL287488B2 (en) Methods for the development and use of minimally polarized microaggregate cell units in tissue applications using lgr4, lgr5 and lgr6 expressing epithelial stem cells
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида